Michael Schaapveld

9.1k total citations · 2 hit papers
155 papers, 5.7k citations indexed

About

Michael Schaapveld is a scholar working on Oncology, Cancer Research and Pathology and Forensic Medicine. According to data from OpenAlex, Michael Schaapveld has authored 155 papers receiving a total of 5.7k indexed citations (citations by other indexed papers that have themselves been cited), including 78 papers in Oncology, 56 papers in Cancer Research and 54 papers in Pathology and Forensic Medicine. Recurrent topics in Michael Schaapveld's work include Breast Cancer Treatment Studies (50 papers), Lymphoma Diagnosis and Treatment (30 papers) and Chemotherapy-induced cardiotoxicity and mitigation (23 papers). Michael Schaapveld is often cited by papers focused on Breast Cancer Treatment Studies (50 papers), Lymphoma Diagnosis and Treatment (30 papers) and Chemotherapy-induced cardiotoxicity and mitigation (23 papers). Michael Schaapveld collaborates with scholars based in Netherlands, United Kingdom and United States. Michael Schaapveld's co-authors include Flora E. van Leeuwen, Berthe M.P. Aleman, Augustinus D. G. Krol, Cécile P.M. Janus, Elisabeth G.E. de Vries, Frederika A. van Nimwegen, R. Otter, Michael Hauptmann, Sarah C. Darby and Pax H.B. Willemse and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Blood.

In The Last Decade

Michael Schaapveld

148 papers receiving 5.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cardiovascular Disease After Hodgkin Lymphoma Treatment

2015 358 citations Michael Schaapveld, Cécile P.M. Janus et al. profile →
Radiation Dose-Response Relationship for Risk of Coronary Heart Disease in Survivors of Hodgkin Lymphoma

2015 324 citations Michael Schaapveld, David J. Cutter et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Michael Schaapveld

Since Specialization

Citations

This map shows the geographic impact of Michael Schaapveld's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Schaapveld with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Schaapveld more than expected).

Fields of papers citing papers by Michael Schaapveld

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Schaapveld. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Schaapveld. The network helps show where Michael Schaapveld may publish in the future.

Co-authorship network of co-authors of Michael Schaapveld

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Schaapveld. A scholar is included among the top collaborators of Michael Schaapveld based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Schaapveld. Michael Schaapveld is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Quantifying cumulative circadian disruption from shift work and associations with health outcomes in a large cohort of nurses 2025 ·SLEEP ·(unknown), Michael Schaapveld, Jelle Vlaanderen, Roel Vermeulen, Hans Kromhout, Flora E. van Leeuwen, (unknown)	0
2	An early economic evaluation of active surveillance for low-risk ductal carcinoma in situ 2024 ·Future Oncology ·(unknown), Michael Schaapveld, Esther H. Lips, Frederieke van Duijnhoven, Jelle Wesseling, Wim H. van Harten, Valesca P. Retèl	0
3	Cancer risks for other sites in addition to breast in CHEK2 c.1100delC families 2024 ·Genetics in Medicine ·(unknown), (unknown), (unknown), Michael Schaapveld, (unknown), (unknown), (unknown), Marjoleine F. Broekema, Margriet Collée, Annemieke H. van der Hout, (unknown), Fenne L. Komdeur, Arjen R. Mensenkamp, Muriel A. Adank, Maartje J. Hooning, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	2
4	Platinum retention in plasma, urine, and normal colonic mucosa in cisplatin-treated testicular cancer survivors 2024 ·PLoS ONE ·(unknown), (unknown), Alwin D. R. Huitema, Jourik A. Gietema, Jos H. Beijnen, Pétur Snæbjörnsson, Michael Schaapveld, Flora E. van Leeuwen, Hilde Rosing, Monique E. van Leerdam, (unknown)	1
5	Risk of male breast cancer after Hodgkin lymphoma 2023 ·Blood ·Simone de Vries, Inge M. Krul, Michael Schaapveld, Cécile P.M. Janus, Saskia E. Rademakers, Judith M. Roesink, Marten R. Nijziel, Yavuz M. Bilgin, Berthe M.P. Aleman, Flora E. van Leeuwen	4
6	Association of Radiation and Procarbazine Dose With Risk of Colorectal Cancer Among Survivors of Hodgkin Lymphoma 2023 ·JAMA Oncology ·(unknown), Rebecca Shakir, Georgios Ntentas, (unknown), Marianne Aznar, (unknown), (unknown), Cécile P.M. Janus, Augustinus D. G. Krol, Judith M. Roesink, Richard W.M. van der Maazen, Josée M. Zijlstra, Sarah C. Darby, Berthe M.P. Aleman, Flora E. van Leeuwen, David J. Cutter, Michael Schaapveld	5
7	Cardiovascular Disease in Testicular Cancer Survivors: Identification of Risk Factors and Impact on Quality of Life 2023 ·Journal of Clinical Oncology ·(unknown), (unknown), Ronald de Wit, Sasja F. Mulder, J. Alfred Witjes, J. Martijn Kerst, Gerard Groenewegen, Joop D. Lefrandt, Flora E. van Leeuwen, Janine Nuver, Michael Schaapveld, Jourik A. Gietema	18
8	Comparison of outcomes between Hodgkin's lymphoma patients treated in and outside clinical trials: A study based on theEORTC‐Dutchlate effects cohort‐linked data 2022 ·European Journal Of Haematology ·(unknown), Michal Kiciński, Michael Schaapveld, (unknown), Berthe M.P. Aleman, Lifang Liu, Flora E. van Leeuwen, Paul Meijnders, Augustinus D. G. Krol, Cécile P.M. Janus, Martin Hutchings, Maja V. Maraldo	1
9	Somatic hits in mismatch repair genes in colorectal cancer among non-seminoma testicular cancer survivors 2022 ·British Journal of Cancer ·(unknown), (unknown), Beatriz Carvalho, Tom van Wezel, Gerrit A. Meijer, Martijn Kerst, Michael Schaapveld, Flora E. van Leeuwen, Pétur Snæbjörnsson, Monique E. van Leerdam	2
10	Single‐item chronotype is associated with dim light melatonin onset in lymphoma survivors with fatigue 2022 ·Journal of Sleep Research ·(unknown), (unknown), Michael Schaapveld, Flora E. van Leeuwen, Eveline M. A. Bleiker, (unknown)	10
11	Long-term risk of subsequent ipsilateral lesions after surgery with or without radiotherapy for ductal carcinoma in situ of the breast 2021 ·British Journal of Cancer ·Maartje van Seijen, Esther H. Lips, Liping Fu, Daniele Giardiello, Frederieke van Duijnhoven, Linda de Munck, Lotte E. Elshof, Alastair M. Thompson, Elinor J. Sawyer, Marc D. Ryser, E. Shelley Hwang, Marjanka K. Schmidt, Paula H.M. Elkhuizen, Jelle Wesseling, Michael Schaapveld	11
12	Characterization of Oligometastatic Disease in a Real-World Nationwide Cohort of 3447 Patients With de Novo Metastatic Breast Cancer 2021 ·JNCI Cancer Spectrum ·Tessa G. Steenbruggen, Michael Schaapveld, Hugo M. Horlings, Joyce Sanders, (unknown), Esther H. Lips, Marie-Jeanne TFD Vrancken Peeters, Niels F. M. Kok, T. Wiersma, Laura J. Esserman, Laura van ‘t Veer, Sabine C. Linn, Sabine Siesling, Gabe S. Sonke	18
13	Pathologic response of ductal carcinoma in situ to neoadjuvant systemic treatment in HER2-positive breast cancer 2021 ·Breast Cancer Research and Treatment ·Emma J. Groen, Marieke E. M. van der Noordaa, Michael Schaapveld, Gabe S. Sonke, Ritse M. Mann, Mette S. van Ramshorst, Esther H. Lips, Marie-Jeanne T. F. D. Vrancken Peeters, Frederieke van Duijnhoven, Jelle Wesseling	6
14	Incidence of metachronous contralateral testicular germ cell tumour and association with chemotherapy 2020 ·European Urology Open Science ·(unknown), (unknown), (unknown), Ronald de Wit, Jourik A. Gietema, Gerard Groenewegen, J.A. Witjes, Hetty A. van den Berg, Janine Nuver, Jacqueline M. Tromp, (unknown), Tineke J. Smilde, Maureen J.B. Aarts, Ben Vanneste, J.L.H. Ruud Bosch, Simon Horenblas, Michael Schaapveld, Richard P. Meijer	0
15	Clinicopathological Risk Factors for an Invasive Breast Cancer Recurrence after Ductal Carcinoma In Situ —A Nested Case–Control Study 2018 ·Clinical Cancer Research ·Lindy L. Visser, Lotte E. Elshof, Michael Schaapveld, Koen Van de Vijver, Emma J. Groen, Mathilde M. Almekinders, Carolien Bierman, Flora E. van Leeuwen, Emiel J. Rutgers, Marjanka K. Schmidt, Esther H. Lips, Jelle Wesseling	31
16	Prostate Brachytherapy and Second Primary Cancer Risk: A Competitive Risk Analysis 2011 ·Journal of Clinical Oncology ·Karel A. Hinnen, Michael Schaapveld, Marco van Vulpen, Jan J. Battermann, Henk G. van der Poel, Inge M. van Oort, Joep G.H. van Roermund, Evelyn M. Monninkhof	66
17	Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age 2010 ·Breast Cancer Research and Treatment ·Dorina M. van der Kolk, Geertruida H. de Bock, Beike Leegte, Michael Schaapveld, Marian J.E. Mourits, Jakob de Vries, Annemieke H. van der Hout, Jan C. Oosterwijk	136
18	Risk of New Primary Nonbreast Cancers After Breast Cancer Treatment: A Dutch Population-Based Study 2008 ·Journal of Clinical Oncology ·Michael Schaapveld, Otto Visser, Marieke W.J. Louwman, Elisabeth G.E. de Vries, Pax H.B. Willemse, R. Otter, Winette T.A. van der Graaf, J.W.W. Coebergh, Flora E. van Leeuwen	167
19	Randomised Phase III study of biweekly 24-h infusion of high-dose 5FU with folinic acid and oxaliplatin versus monthly plus 5-FU/folinic acid in first-line treatment of advanced colorectal cancer 2006 ·Annals of Oncology ·Geke A.P. Hospers, Michael Schaapveld, J.W.R. Nortier, J. Wils, Aart van Bochove, Robert S. de Jong, G.J. Creemers, Z. Erjavec, (unknown), P. H. Th. J. Slee, C J Gerrits, Jeff M. Smit, Nanno H. Mulder	29
20	Surgery by consultant gynecologic oncologists improves survival in patients with ovarian carcinoma 2005 ·Cancer ·M.J.A. Engelen, (unknown), Pax H.B. Willemse, Jan G. Aalders, Elisabeth G.E. de Vries, Michael Schaapveld, R. Otter, Ate G.J. van der Zee	234

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact